CDK4/6 inhibitors in lung cancer: current practice and future directions

CDK4/6 inhibitors in lung cancer: current practice and future directions

Lung cancer is the leading cause of cancer-related deaths worldwide, and ∼85% of lung cancers are classified as nonsmall cell lung cancer (NSCLC). These malignancies can proliferate indefinitely, in part due to dysregulation of the cell cycle and the resulting abnormal cell growth. The specific acti...

Full description

Bibliographic Details
Main Authors: Shuoshuo Lv, Jie Yang, Jiayuh Lin, Xiaoying Huang, Haiyang Zhao, Chengguang Zhao, Lehe Yang
Format: Article
Language:English
Published: European Respiratory Society 2024-02-01
Series:European Respiratory Review
Online Access:http://err.ersjournals.com/content/33/171/230145.full

Internet

http://err.ersjournals.com/content/33/171/230145.full

Similar Items